Burkholderia pseudomallei, the causative agent of melioidosis, is intrinsically resistant to a broad range of antibiotics, including aminoglycosides. In Sarawak, Malaysia, a high proportion of melioidosis cases are caused by gentamicin-susceptible isolates. There are limited epidemiological and clinical data on these infections. We conducted a retrospective study of culture-confirmed melioidosis among adults admitted to Bintulu Hospital in Sarawak, Malaysia, from January 2011 until December 2016. One hundred forty-eight adults with culture-confirmed melioidosis were identified. Of 129 (87%) tested, 84 (65%) had gentamicin-susceptible B pseudomallei. The average annual incidence of melioidosis was 12.3 per 100 000 population, with marked variation between districts ranging from 5.8 to 29.3 per 100 000 population. Rural districts had higher incidences of melioidosis and overwhelmingly larger proportions of gentamicin-susceptible B pseudomallei infection. Significantly more patients with gentamicin-susceptible infection had no identified risk factors, with diabetes less frequently present in this group. Ninety-eight percent had acute presentations. Pneumonia, reported in 71%, was the most common presentation. Splenic abscesses were found in 54% of those imaged. Bacteremia was present in 88%; septic shock occurred in 47%. Forty-five (35%) patients died. No differences in clinical, laboratory, or outcome characteristics were noted between gentamicin-susceptible and gentamicin-resistant infections. Gentamicin-susceptible B pseudomallei infections are common in Sarawak and dominate in the high-incidence rural interior regions. Clinical manifestations and outcomes are the same as for gentamicin-resistant B pseudomallei infections. Further studies are required to determine if all gentamicin-susceptible B pseudomallei infections in Sarawak are clonal and to ascertain their environmental drivers and niches.
15 August 2020 in SN Comprehensive Clinical Medicine
As a causal organism in infective endocarditis, Burkholderia pseudomallei is rare. Burkholderia pseudomallei is intrinsically resistant to aminoglycosides but a gentamicin-susceptible strain was discovered in Sarawak, Malaysian Borneo in 2010. We report the first occurrence of infective endocarditis due to the gentamicin-susceptible strain of B. pseudomallei. A 29-year-old man presented with pneumonia and melioidosis septicaemia. His condition was complicated with infective endocarditis and septic emboli to the brain. Despite difficulties in reaching a diagnosis, the patient was successfully treated using intravenous gentamicin and ceftazidime and was discharged well. The role of gentamicin in the treatment of the gentamicin-susceptible strain of B. pseudomallei remains unclear.
We report a first case of ceftazidime-resistant pediatric melioidosis involving a previously healthy seven-year-old boy who presented with right lobar pneumonia complicated with a 5-cm lung abscess. Ceftazidime was initiated on Day-6 of admission when Burkholderia pseudomallei (ceftazidime-susceptible, minimum inhibitory concentration [MIC] 1.0 mcg/mL) was isolated from blood. Despite ceftazidime therapy at the recommended dosage, he developed fulminant septic shock and respiratory failure on Day-18 of hospitalization, requiring invasive ventilation, hemodynamic support, and continuous renal replacement therapy. His antibiotic was empirically escalated to meropenem; ceftazidime-resistant B. pseudomallei (MIC 32 mcg/mL) was subsequently isolated from blood and endotracheal secretions. He improved after two weeks of intensive care and was discharged well after two months of hospitalization. Our literature review on ceftazidime-resistant B. pseudomallei infection indicates that acquired resistance is a rare but potentially lethal treatment-related complication. All melioidosis patients should be carefully monitored during treatment with ceftazidime (or other β-lactams) for the development of antimicrobial resistance.
A previously healthy woman in her mid-70s presented with right upper quadrant abdominal pain, fever, intermittent chills and malaise for 1 week. She was clinically septic with raised inflammatory markers. Her blood culture revealed Pasteurella multocida, which was susceptible to penicillin and amoxicillin-clavulanic acid. CT of liver revealed an abscess of 8.0×7.9×8.5 cm at the left lobe of the liver. However, the abscess was not amenable for surgical or radiological drainage. She was a farmer and had close contact with her pet cats. She was occasionally scratched by her cats when caring for them. The liver abscess resolved completely without drainage after prolonged antimicrobial therapy of 109 days. She commenced on 63 days of intravenous antimicrobials and 46 days of oral amoxicillin-clavulanic acid. This case illustrated P. multocida bacteraemia with a large liver abscess in an immunocompetent adult after non-bite exposure.
20 October 2026 in The American Journal of Tropical Medicine and Hygiene
: Melioidosis, caused by Burkholderia pseudomallei , is endemic in Southeast Asia. Over 90% of cases present acutely. The reactivation of latent melioidosis in endemic regions is difficult to diagnose, and the incidence is unknown. We report two previously healthy middle-age women from Limbang, Malaysian Borneo, who were newly diagnosed with systemic lupus erythematosus. They developed fulminant sepsis due to culture-confirmed melioidosis 4 to 8 weeks after starting immunosuppressive therapy. They had pneumonia and multiorgan microabscesses. One patient survived, whereas the other succumbed to illness. Diagnosing the reactivation of latent melioidosis in endemic regions is impeded by substantial gaps in clinical evaluation and laboratory diagnostic capacity, particularly within resource-limited health care systems. Maintaining high clinical vigilance for reactivation, promptly identifying disseminated disease, and initiating targeted therapy early are critical during the initiation and administration of immunosuppressive treatment. Pre-immunosuppression risk assessment and potential prophylactic strategies in high-risk individuals may help reduce the associated morbidity and mortality.